Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesCNS Pharmaceuticals Inc

CNS Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.01 USD -0.33 ( 7.60%)
Last update at 2026-11-05T21:00:00Z
VOLUME
3408
Market Cap
8.33M

Momentum Score

…

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.00
Low
4.11
High
52 Week Price Range
1.90
Low
10.59
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
4.34
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.07
ROE
-106.62%
Net Debt
-6.87M
ROCE
-350.14%
Diluted EPS TTM
-15.39

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -15.85M -14.86M -18.85M -15.27M -14.04M
Net income -15.85M -14.86M -18.85M -15.28M -14.05M
Selling general administrative 6.21M 5.61M 4.77M 5.97M 4.68M
Selling and marketing expenses - - 0.00M - -
Gross profit - -0.00M -0.00M - -
Reconciled depreciation 0.00M 0.00M 0.01M 0.01M 0.01M
Ebit -15.84M -14.84M -18.87M -15.27M -14.03M
Ebitda -15.83M -14.84M -18.86M -15.26M -14.01M
Depreciation and amortization 0.00M 0.00M 0.00M 0.01M 0.01M
Operating income -15.99M -14.90M -18.87M -15.27M -14.03M
Other operating expenses 15.99M 14.90M 18.87M 15.27M 14.03M
Interest expense 0.02M 0.02M 0.01M 0.01M 0.01M
Interest income 0.15M 0.06M 0.03M - -
Net interest income 0.14M 0.04M 0.01M -0.01M -0.01M
Income tax expense - - -0.00M 0.01M 0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 15.99M 14.90M 18.86M 15.27M 14.03M
Cost of revenue - 0.00M 0.00M - -
Total other income expense net 0.14M 0.04M 0.01M -0.01M -0.01M
Net income from continuing ops -15.85M -14.86M -18.61M -15.27M -14.04M
Net income applicable to common shares - - - - -14.04M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 8.62M 8.70M 1.70M 13.05M 8.76M
Other current assets 0.90M 1.31M 0.84M 2.51M 2.47M
Total liab 4.10M 2.52M 6.13M 4.92M 2.14M
Total stockholder equity 4.52M 6.18M -4.43M 8.13M 6.62M
Deferred long term liab - - - - 0.33M
Other current liab 3.77M 2.20M 5.83M 0.83M 0.22M
Common stock 0.00M 0.00M 0.01M 0.00M 0.03M
Capital stock 0.00M 0.00M 0.01M 0.00M 0.03M
Retained earnings -100.28M -84.42M -69.57M -50.72M -34.98M
Other assets - - 0.00M - 1.26M
Cash 7.20M 6.46M 0.55M 10.06M 5.00M
Total current liabilities 4.10M 2.52M 6.13M 4.92M 2.14M
Current deferred revenue - - -5.83M - -
Net debt -6.87M -6.14M -0.25M -9.65M -4.62M
Short term debt 0.33M 0.33M 0.30M 0.41M 0.39M
Short long term debt 0.33M 0.33M 0.30M 0.41M 0.39M
Short long term debt total 0.33M 0.33M 0.30M 0.41M 0.39M
Other stockholder equity 104.80M 90.60M 65.13M 58.85M 41.58M
Property plant equipment - - - - 0.02M
Total current assets 8.10M 8.66M 1.39M 12.56M 7.48M
Net tangible assets - - - - 6.62M
Net receivables 0.00M 0.88M - - -
Accounts payable - 2.20M 5.83M 3.68M 1.52M
Non currrent assets other 0.50M 0.04M 0.31M 0.48M 1.26M
Non current assets total 0.52M 0.04M 0.31M 0.49M 1.28M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.00M -0.00M -0.00M -0.01M
Change to liabilities - - - - 0.58M
Total cashflows from investing activities -0.02M -0.00M -0.00M - -0.01M
Net borrowings -0.30M -0.30M -0.44M - -0.48M
Total cash from financing activities 14.57M 23.03M 4.64M 15.61M 4.51M
Change to operating activities - - - - -1.82M
Net income -15.85M -14.86M -18.85M -15.27M -14.04M
Change in cash 0.74M 5.91M -9.51M 5.05M -9.03M
Begin period cash flow 6.46M 0.55M 10.06M 5.00M 14.04M
End period cash flow 7.20M 6.46M 0.55M 10.06M 5.00M
Total cash from operating activities -13.81M -17.11M -14.14M -10.56M -13.54M
Issuance of capital stock 14.05M 23.38M 7.51M 16.04M 4.65M
Depreciation 0.00M 0.00M 0.00M 0.01M 0.01M
Sale purchase of stock -0.00M 0.00M - - -
Other cashflows from financing activities 0.82M -0.05M 2.76M 0.00M 0.33M
Change to netincome - - - - 1.72M
Capital expenditures 0.02M 0.00M 0.00M 0.00M 0.01M
Change in working capital 1.85M -3.69M 3.70M 3.16M -1.24M
Stock based compensation 0.19M 0.84M 1.01M 1.20M 1.72M
Other non cash items 0.00M 0.60M 0.00M 0.34M 7.01M
Free cash flow -13.83M -17.12M -14.14M -10.56M -13.54M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
CNSP
CNS Pharmaceuticals Inc		 -0.33
7.60%		 4.01 - - - 0.46 0.40
NVO
Novo Nordisk A/S		 -1.88
4.46%		 40.30 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -6.54
1.19%		 542.50 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -27.77
2.98%		 902.90 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

CNS Pharmaceuticals Inc

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.

2100 West Loop South, Houston, TX, United States, 77027

800 946 9185

https://cnspharma.com

8

Name Title Year Born
Mr. John Michael Climaco Esq., J.D. Chairman, CEO & Pres 1969
Mr. Christopher S. Downs CPA, CTP, FP&A Chief Financial Officer 1978
Dr. Sandra L. Silberman M.D., Ph.D. Chief Medical Officer 1955
Dr. Waldemar Priebe Ph.D. Founder NA
Dr. Donald H. Picker Ph.D. Chief Science Officer 1946
Mr. John Michael Climaco Esq., J.D. CEO, President & Director 1969
Mr. Christopher S. Downs C.P.A., CTP, FP&A Chief Financial Officer 1979
Dr. Sandra L. Silberman M.D., Ph.D. Chief Medical Officer 1956
Mr. Christopher S. Downs CPA, CTP, FP&A Senior Vice President of Finance 1979
Mr. Rami Levin M.B.A. President, CEO & Director 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…